The company has increased its dividend by 33% since 2022 and currently pays annually.
CVS Health Corporation (CVS) currently holds a consensus from Wall Street analysts, with 20 out of 24 experts recommending it as a top pick as of late April 2026. Trading near $78.38 , the stock is widely considered an attractive value play due to its low valuation relative to its $400+ billion annual revenue and robust cash flow. Key Investment Highlights
: The stock trades at roughly 11x forward earnings , significantly below its historical average of 12-15x. Morningstar estimates a fair value of $97.00 . should i buy cvs stock
: The company is still managing significant debt from past major acquisitions, such as Aetna. Summary of Analyst Sentiment (April 2026) Percentage Strong Buy Buy Hold/Sell
: While 2026 rates were better than feared, fluctuating Medicare reimbursement and higher medical utilization costs can squeeze insurance margins. The company has increased its dividend by 33%
Some analysts project a 12-month price target averaging , implying over 20% upside.
: Ongoing antitrust scrutiny of pharmacy benefit managers (PBMs) and potential changes to Medicare Advantage rates remain key risks for the 2027 fiscal year. Key Investment Highlights : The stock trades at
: After a challenging 2024, the company's 2025 revenue hit a record $402.1 billion , with adjusted EPS rising over 24% to $6.75.